CORT Stock Corcept Therapeutics Incorporated

$63.62
1d-2.09%5d-12.78%1m-45.29%ytd+82.82%
At close · Nov 20, 4:00 PM ET
After hours $63.62 +0% · Nov 20, 4:00 PM ET
52w low $28.6636% of range$126.38 52w high
Price

Today’s call · CORT

All live ideas →

5 of 6 technical checks lean bearish

CORT is in a downtrend, momentum soft. $70 is the level overhead; $60 the first support below.

No open idea.From $63.62 the reward-to-risk to $60 against $70 is 0.6 — below the 3:1 bar.
What would create one:
  • A close below $60 on rising volume (breakdown).
  • A bounce to $70 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · belowPrice vs 200-day · below50d vs 200d avg · aboveMACD · bearishRSI momentum · 215-day tape · -12.8%
momentumRSI 20.9 is oversold — the decline has been unusually fast.
signalCORT’s 50-day average is above the 200-day — long-term trend alignment is bullish.
All readings
TrendDowntrend · below 50-day & below 200-day
MomentumRSI 20.9 · oversold · MACD bearish
Trend strengthADX 52.2 · strong trend
Location-35.8% vs 50-day MA
52-week range-49% from high · +98% from low
VolatilityATR 4.91 · ~7.7%/day
RSI 14
20.9
MACD
-9.80
ADX 14
52.2
ATR 14
4.91
SMA 50
$99.03
SMA 200
$77.18

Levels that matter

$70round+10.0%
$77.18sma 200+21.3%
$77.72swing zone · 2×+22.2%
$60round−5.7%
$50round−21.4%
$32.1552w low−49.5%

Compare with…

Analyst overview · Nov 15

Corcept Therapeutics (CORT) faces deep downtrend, breakout risk

Corcept Therapeutics Incorporated closed at $72.94 on November 13, a level well below its 40‑week average and its 200‑day SMA of $76.5. The daily price action follows a weekly downtrend, and the balance of evidence points to a bearish outlook for the next two to six weeks. A close under the round $70 barrier would trigger the downside math, with targets near $33.4 and $32.15 offering a reward‑to‑risk ratio around five‑to‑one.

Why it matters

The stock has been shedding value since a sharp peak at $121.19 on October 12, a drop of almost 40%. That move was not driven by any specific corporate news; the news feed is empty, indicating the market is pricing in broader forces. The broader market, represented by the S&P 500, rose 2.59% over the past five days while CORT only gained 0.23%, leaving the stock lagging the index by roughly 2.0% on a five‑day basis. The healthcare sector ETF XLV outperformed the stock by 2.0% as well, reinforcing the view that CORT is underperforming both its peers and the market.

Analysts remain optimistic, with a consensus “buy” rating and a mean price target of $142.6, nearly 49% above the current price. However, that target is an outlier compared with the stock’s recent trading range; the low end of the analyst spread sits at $50, still far above today’s level. The disparity suggests that the consensus may be pricing in a recovery that the technical picture does not support.

From a technical standpoint the stock sits below its 50‑day SMA of $103.7 and its 200‑day SMA of $76.5, confirming a long‑term downtrend. The 14‑day RSI is at 26, indicating oversold conditions but also reflecting weak momentum. Volume is 14.8% below its 20‑day average, showing limited buying interest. The 52‑week range spans $32.15 to $123.57, with the price now 41% below the high and 127% above the low, underscoring the depth of the decline.

Both sides of the debate recognize the gap between analyst optimism and technical weakness. Proponents of the upside cite the large upside potential implied by the $142.6 target and the fact that the stock remains above its 52‑week low, leaving room for a rebound. Critics point to the daily trend aligning with the weekly downtrend, the lag versus SPY and XLV, and the lack of any catalyst to reverse the slide. The evidence leans heavily toward the downside case.

What the evidence says

On the long‑term horizon the thesis of a sustained downtrend remains intact. The price is well below its 40‑week average, the 200‑day SMA is acting as a resistance line, and the stock has not broken above the weekly trend line since the peak in October. The combination of a low RSI, weak volume, and a price that sits 41% below its 52‑week high confirms that the bearish phase is still in play.

Looking ahead to the next two to six weeks the balance of evidence is negative, with a high conviction rating. The assessment notes three of four conviction points: the daily trend runs with the weekly downtrend, the stock lags the S&P 500 by 28.6% over 50 days, and it lags the healthcare sector XLV by 35.3% over the same period. The breakout math is aligned for a downside move, requiring a daily close below the round $70 level. The stop is set at $77.67, based on the 200‑day SMA plus a quarter of the 14‑day ATR, and the reward‑to‑risk on the first target ($33.4) is 4.8‑to‑1.

The strongest argument against this bearish reading would be a rapid rally that pushes the price above the $77.72 swing‑zone resistance and sustains a weekly close above that level. Even if such a move occurred, the underlying lag versus the broader market and sector would still need to be overcome, and the technical structure would remain challenged.

Levels that matter

The price is currently holding above the 200‑day SMA at $76.5, which has acted as a ceiling in prior rallies. Sellers have repeatedly stepped in around that level, and the weekly trend remains down, indicating that the structure is still anchored above $76.5. A weekly close above $77.72, the swing‑zone resistance, would signal the end of the current downtrend and could open the path to higher levels.

The breakout threshold for the downside scenario is a daily close below the round $70 level. If that level is breached, the math projects a first target near $33.4, derived from a swing‑zone support, and a second target at $32.15, the 52‑week low. Both targets offer a reward‑to‑risk ratio close to five‑to‑one, satisfying the 3‑to‑1 criterion. The stop at $77.67 provides a tight risk limit relative to the potential upside.

What would change the picture

A weekly close above $77.72 would alter the current narrative, indicating that the downtrend may be losing steam. The non‑price factor that could trigger such a shift would be a materially positive earnings surprise on November 4, where the earnings per share beats expectations and guidance is raised.

What to watch

  • November 4 earnings: the earnings per share figure and any forward‑looking guidance will be the key number.
  • Sector catalysts: any FDA approvals or major biotech mergers affecting the healthcare sector could move CORT before its own news.
  • Valuation: the consensus mean target of $142.6 implies a price‑to‑earnings multiple far above current levels, highlighting the disconnect between analyst expectations and the technical reality.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.